BullFrog AI vs Lisata Therapeutics
BFRG and LSTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BFRG and LSTA compare
BullFrog AI and Lisata Therapeutics are about the same size, with market caps of $9.0M and $9.8M.
Lisata Therapeutics scores higher on the StockData Score (6 against 3 for BullFrog AI), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BFRG | LSTA |
|---|---|---|
| Size and price | ||
| Market cap | $9.0M | $9.8M |
| Share price | $0.488 | $1.09 |
| Change, 1 year | −51.2% | −47.3% |
| Change, 5 years | – | −92.6% |
| Beta (5Y) | 4.87 | −1.65 |
| Employees | 9 | 21 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 98.2× |
| P/B | 1.3× | 1.2× (better) |
| FCF yield | – | −125% |
| Growth | ||
| Revenue growth (TTM) | – | −90.7% |
| Profitability | ||
| Operating margin | – | −16427% |
| Net margin | – | −14621% |
| FCF margin | – | −12323% |
| Return on equity | −131% | −99.9% (better) |
| Return on invested capital | – | −1645% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1105.4× | – |
| Current ratio | 10.57 (better) | 3.69 |
| Altman Z-score | 1.34 (better) | −74.72 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −111% | −6.0% (better) |
| Shareholder yield | −111% | −6.0% (better) |
| Ownership | ||
| Held by institutions | 7.5% | 12.1% |
| Held by insiders | 13.7% | 11.6% |
| Insider net buying, 12 months | $71.5K | – |
| Short interest, % of float | – | 0.43% |
Go deeper
- BFRG stock overview
- BFRG income statement
- BFRG valuation and score
- LSTA stock overview
- LSTA income statement
- LSTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.